Cargando…
Antivirale COVID-19-Therapie für Risikogruppen
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951130/ https://www.ncbi.nlm.nih.gov/pubmed/36826675 http://dx.doi.org/10.1007/s15006-023-2421-2 |
| _version_ | 1784893321339994112 |
|---|---|
| author | Dikken, Birke |
| author_facet | Dikken, Birke |
| author_sort | Dikken, Birke |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9951130 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Medizin |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99511302023-02-24 Antivirale COVID-19-Therapie für Risikogruppen Dikken, Birke MMW Fortschr Med Pharmaforum Springer Medizin 2023-02-24 2023 /pmc/articles/PMC9951130/ /pubmed/36826675 http://dx.doi.org/10.1007/s15006-023-2421-2 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Pharmaforum Dikken, Birke Antivirale COVID-19-Therapie für Risikogruppen |
| title | Antivirale COVID-19-Therapie für Risikogruppen |
| title_full | Antivirale COVID-19-Therapie für Risikogruppen |
| title_fullStr | Antivirale COVID-19-Therapie für Risikogruppen |
| title_full_unstemmed | Antivirale COVID-19-Therapie für Risikogruppen |
| title_short | Antivirale COVID-19-Therapie für Risikogruppen |
| title_sort | antivirale covid-19-therapie für risikogruppen |
| topic | Pharmaforum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951130/ https://www.ncbi.nlm.nih.gov/pubmed/36826675 http://dx.doi.org/10.1007/s15006-023-2421-2 |
| work_keys_str_mv | AT dikkenbirke antiviralecovid19therapiefurrisikogruppen |